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Abstract
Background: Our study aims to determine the value of diffusion-weighted imaging (DWI) combined with
conventional magnetic resonance imaging (MRI) in the diagnosis of thecomas/fibrothecomas and their differential
diagnosis with malignant pelvic solid tumors.
Methods: In total, 36 thecomas/fibrothecomas and 40 malignant pelvic solid tumors were included in our study. All
patients underwent 1.5 T conventional MRI and DWI examinations except one patient with a fibrothecoma in
whom DWI examination was not performed. The clinical features and characteristics of conventional MRI and DWI
of these two groups were analyzed. Apparent diffusion coefficient (ADC) values were measured and compared
between groups. Univariate analysis, multivariate logistic regression analysis, and the receiver operating
characteristic curve were used for statistical analysis.
Results: All the thecomas/fibrothecomas showed isointensity on T1 weighted imaging (T1WI) and 77.8 % (28/36)
lesions showed hypo- to isointensity on T2 weighted imaging (T2WI). After administration of contrast medium,
94.4 % (34/36) tumors appeared as minor to mild enhancement. On DWI, they showed a diversity of low to very
high signal intensity. All malignant pelvic masses manifested as hyperintensity on T2WI and 87.5 % (35/40) tumors
showed very high signal (grade 3) on DWI. Higher area under the curve (AUC) and specificity could be achieved by
using the lowest ADC value than the mean ADC value. Multivariate logistic regression analysis showed that shape,
signal intensity on T2WI, capsule, and the lowest ADC value were the important indicators in discriminating
thecomas/fibrothecomas from malignant pelvic solid tumors.
Conclusions: The combination of DWI and conventional MRI is of great value in the diagnosis of thecomas/
fibrothecomas and their differential diagnosis with malignant pelvic solid tumors.
Keywords: Thecoma, Malignant pelvic solid tumors, Conventional magnetic resonance imaging, Diffusion-weighted
imaging, Apparent diffusion coefficient value
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Background
Ovarian thecomas are rare mesothelial tumors with a
sex-cord stromal origin, which account for 0.5–1 % of
primary ovarian tumors and are the most common solid
benign tumors of the ovary [1, 2]. Thecomas are com-
posed of theca-like cells with lipid-rich cytoplasm and
may have a variable component of fibroblasts (then
called fibrothecomas). Thecomas/fibrothecomas are
mostly benign tumors and are rarely malignant [3, 4].
They are often asymptomatic and are usually identified
incidentally [5]. When symptomatic, patients commonly
complain of abdominal pain, abdominal distention, or
abdominal masses. They mostly affect menopausal and
postmenopausal women but can also occur in young pa-
tients with an average age of onset between 55 and
60 years [6]. They may also present with ascites and
pleural effusions, known as Meigs syndrome [7, 8].
A correct diagnosis of ovarian thecoma/fibrothecoma
is of great value owing to their benign nature. However,
given the low incidence and complicated clinical and im-
aging manifestations of the disease, accurate diagnosis
before operating is sometimes difficult. One particular
lesion that requires consideration for differential diagno-
sis is malignant pelvic solid tumors. Though a few cases
are mixed cystic-solid and even mainly cystic, most the-
comas/fibrothecomas are overwhelmingly solid masses.
One of the magnetic resonance imaging (MRI) criteria
to diagnose malignant ovarian tumors is a solid mass or
a mass with large solid components [2]. Other patho-
logical elements such as edema, degenerative changes,
intracellular lipid and varying proportions of theca-like
cells and fibroblasts together also contribute to the com-
plexity of their MRI features. In addition, ascites and
high levels of CA125 can occur in some patients, which
is suggestive of ovarian malignancy in the menopausal
women [9]. All the above factors occasionally result in a
dilemma in the differential diagnosis of ovarian theco-
mas/fibrothecomas with malignant pelvic solid tumors.
Differential diagnosis of these tumors is of great import-
ance because correct diagnosis of thecomas/fibrotheco-
mas preoperatively can decrease patient anxiety and
different diseases will have different patient management
strategies. MRI has proven to be a useful method to
diagnose thecomas/fibrothecomas. However, reports on
MRI features of this disease are extremely limited, espe-
cially those including signal characteristics on DWI. To
our knowledge, differentiating thecomas/fibrothecomas
from malignant pelvic solid masses with apparent diffu-
sion coefficient (ADC) values by a receiver operating
characteristic (ROC) curve analysis has not been re-
ported. Therefore, the purposes of our study were to
analyze the MRI characteristics of thecomas/fibrotheco-
mas in detail and to differentiate thecomas/fibrotheco-
mas from malignant pelvic solid masses with MRI




All ovarian tumors diagnosed by the department of ob-
stetrics and gynecology in our hospital between May
2009 and March 2015 were retrospectively analyzed. In
total, 36 thecomas/fibrothecomas (6 thecomas and 30
fibrothecomas) in 34 patients and 40 malignant pelvic
solid tumors were included in our study. The 40 malig-
nant pelvic solid tumors include: 22 serous adenocarcin-
omas, 4 endometroid adenocarcinomas, 3 clear cell
adenocarcinomas, 1 undifferentiated carcinoma, 1 dys-
germinoma, 2 granular cell tumors, 3 carcinosarcomas,
2 metastatic tumors, and 2 leiomyosarcomas. The dis-
ease stage information for the malignant pelvic solid tu-
mors was as follows: stage I, n = 4; stage II, n = 8; stage
III, n = 21; and stage IV, n = 7. The malignant pelvic solid
masses were defined as tumors whose solid components
accounted for more than 75 % of the entire lesion. All
patients were confirmed by surgery and pathology. They
all underwent 1.5 T MRI examinations which included
conventional precontrast and postcontrast MRI and
DWI except one patient with a fibrothecoma in whom
DWI was not performed. The study was approved by
our institutional ethics committee and written informed
consent was obtained from all patients.
MRI protocol
All patients underwent MRI with a 1.5 T clinical MR im-
aging system (Twinspeed, GE Medical Systems, Milwau-
kee, WI, USA), using a pelvic phased-array coil. The
imaging protocol involved axial non-contrast T1
weighted imaging (T1WI) (TR/TE range, 400–600/10–
14 ms) and axial T2 weighted imaging (T2WI) (TR/TE
range, 4000–6000/100–120 ms) performed with a chem-
ical shift-selective fat saturation pulse using the follow-
ing parameters: slice thickness, 6 mm; gap, 1 mm; field
of view (FOV), 32–42 cm; matrix, 256 × 256; and num-
ber of excitation, 2. Sagittal T1WI and T2WI (TR/TE,
3000–6000/100–110 ms) fast spin-echo imaging without
chemical shift-selective fat saturation pulse was also per-
formed, as well as postcontrast enhanced axial and sagit-
tal T1WI with the same parameters, apart from a slice
thickness of 5–7 mm. DWI was acquired in the axial
plane prior to administration of contrast medium using
a single-shot echo-planar imaging sequence (TR/TE ef-
fective range, 8000–10,000/70–100; slice thickness/inter-
section gap, 6/1 mm; FOV, 32 to 42 cm; matrix, 128 ×
128; number of excitation, 2). A b-value of 0 and 1000 s/
mm2 was also used in three orthogonal (Z, Y, and X)
directions.
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MRI analysis
MRI data were reviewed independently on an Advantage
Windows workstation 4.2 (GE Healthcare, Milwaukee,
WI, USA) by two radiologists with 18 and 13 years of
experience in gynecological imaging. They both were
blind to the pathological results and discrepancies were
resolved by consensus. For the two groups of diseases,
the following MRI characteristics were recorded: morph-
ology (round/oval, lobulated or irregular); size (the lar-
gest diameter measured along the three dimensions);
border (clear or not); capsule (present or not); ascites
(none, minor, small, large); signal intensity on T1WI and
T2WI (hypo-, iso-, hyperintensity, or mixed intensity,
compared with the myometrium); degree of enhance-
ment (minor: clearly less than the myometrium; mild:
less than the myometrium; marked: similar to the myo-
metrium; severe: more than the myometrium); DWI sig-
nal intensity (graded as 1–3; grade 1: low to slightly high
signal, obviously lower than the endometrium; grade 2:
high signal, but lower than the endometrium; grade 3:
very high, similar to or higher than the endometrium).
In addition, for the thecoma/fibrothecomas group, we
also evaluated the following features: location (left, right,
or both sides); component (solid or mixed cystic/solid);
extent of degeneration (none, <5 %, 5–30 %, and >30 %
of the entire lesion); compared degenerative changes be-
tween tumors larger and those smaller than 6 cm;
pleural effusion; visibility of ipsilateral ovaries; appear-
ance of peripheral cystic areas; and occurrence of
endometrial carcinoma and endometrial hyperplasia
(endometrial thickness more than 5 and 16 mm in post-
menopausal and premenopausal women, respectively
[10, 11]).
Data calculation and analysis
The solid component of each tumor was recognized on
T2WI and postcontrast T1WI and was then matched on
ADC maps. The ADC values of the solid components of
each lesion was measured on diffusion weighted images
by one radiologist with the manufacturer’s software
(FuncTool; GE, Medical Systems, Milwaukee, WI, USA)
at an Advantage Windows workstation 4.2 (GE Health-
care). In order to balance variability and error, the lar-
gest possible regions of interest (ROIs) ranging from 15
to 500 mm2 were manually placed in the solid portions
of the tumors and the degenerative regions were avoided
to the best of our ability. No more than three ROIs were
drawn in each lesion, and the mean ADC values were
calculated and used in our study.
Statistical analysis
Continuous variables were expressed as means ±
standard deviation (SD). The statistical comparisons
for the clinical and image features between groups
were conducted by using the univariate analysis (the
χ2 test and the Student’s t test/Mann-Whitney U test).
The ROC curve was also used to compare the ability
of the lowest ADC value and the mean ADC value in
differentiating thecomas/fibrothecomas from malignant
pelvic solid masses. The cutoff value was obtained by cal-
culating the maximum Youden index (Youden index =
sensitivity + specificity − 1). The multivariate logistic ana-
lysis was performed to show the true prognostic value of
ADC value and the other MRI characteristics. Age and le-
sion size were excluded from the logistic regression ana-
lysis because they were not significantly different between
the two groups. All analysis was performed with SPSS ver-
sion 19.0 for Windows (SPSS, Chicago, IL, USA). P < 0.05
was considered statistically significant.
Results
Clinical information
Our research included 36 thecomas/fibrothecomas in 34
patients and 40 malignant pelvic solid tumors. The mean
age of patients with thecomas/fibrothecomas was 59.0 ±
13.2 years, and the earliest onset age was 18 years. In the
malignant pelvic solid tumor group, the mean patient
age was 55.3 ± 14.5 years. Most of the thecomas/
fibrothecomas were incidentally identified by health ex-
aminations, while the primary complaints included post-
menopausal vaginal bleeding and abdominal pain.
CA125 tests were performed in 20 of 34 and 31 of 40
patients with thecomas/fibrothecomas and malignant
pelvic masses, respectively. Among these, elevated
CA125 levels (>35 U/mL) appeared in 25.0 % (5/20) and
71.0 % (22/31) of patients, respectively.
MRI features and ADC analysis
In the thecomas/fibrothecomas (Figs. 1, 2, and 3), all le-
sions showed isointensity on T1WI and 77.8 % (28/36)
lesions showed hypo- to isointensity on T2WI. In total,
94.4 % (34/36) tumors appeared as minor to mild en-
hancement. On DWI, they showed a diversity of low to
very high signal intensity. Solid masses accounted for
86.1 % (31/36), while only 13.9 % (5/36) tumors were
cystic-solid masses (Fig. 4). 58.3 % (21/36) masses
showed peripheral cystic areas (Fig. 5). In malignant pel-
vic tumors (Fig. 6), all manifested as hyperintensity on
T2WI and 87.5 % (35/40) masses show very high signal
(grade 3) on DWI. MRI characteristics of thecomas,
fibrothecomas, and malignant pelvic solid masses are
summarized in Table 1.
In the univariate analysis, there were significantly stat-
istical differences in shape, signal intensity on T2WI, en-
hancement degree, pelvic fluid, border, capsule, and the
lowest and mean ADC values between groups (P < 0.05).
Age and lesion size were not significantly different (P >
0.05). The lowest and mean ADC value of thecomas/
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fibrothecomas were significantly higher than malignant
pelvic solid tumors (lowest ADC: average, 1.16 ± 0.27 ×
10−3 mm2/s vs 0.81 ± 0.20 × 10−3 mm2/s; range, 0.73 −
1.77 × 10−3 mm2/s vs 0.29 − 1.21 × 10−3 mm2/s; 95 %
confidence interval, 1.07 − 1.25 × 10−3 mm2/s vs 0.74 −
0.87 × 10−3 mm2/s) (mean ADC: average, 1.25 ± 0.28 × 10
−3 mm2/s vs 0.89 ± 0.20 × 10−3 mm2/s; range, 0.73 −
1.95 × 10−3 mm2/s vs 0.42 − 1.23 × 10−3 mm2/s; 95 %
confidence interval, 1.15 − 1.34 × 10−3 mm2/s vs 0.83 −
0.96 × 10−3 mm2/s). In the ROC curve analysis, higher
Fig. 1 Female, 77 years, fibrothecoma smaller than 6 cm on the right ovary. a Axial T1WI showed a solid mass with homogenous isointensity
(arrow). b On axial fat saturated T2WI, the mass showed homogenous hypointensity (long arrow) compared with myometrium (short arrow). There
was no degenerative change. c On axial contrast-enhanced fat saturated T1WI, the mass (long arrow) revealed minor enhancement, weaker than
the myometrium (short arrow). d On DWI, the mass appeared as a slightly high signal (grade 1). e On ADC map, the mean ADC value was 1.41 ×
10−3 mm2/s. f On sagittal T2WI, the manifestation was similar to Fig. 1b
Fig. 2 Female, 27 years, fibrothecoma larger than 6 cm on the right ovary. a Axial T1WI showed a solid mass with isointensity (arrow). b On axial
fat saturated T2WI, the mass (arrow) was hypointensity compared with the myometrium. Hyperintensity in the mass represented degenerative
changes (short arrow). This tumor was accompanied with endometrial hyperplasia (bold arrow). c On axial contrast-enhanced fat saturated T1WI,
the mass (long arrow) revealed minor enhancement, weaker than the myometrium (short arrow). d On DWI, the mass appeared as a slightly high signal
(grade 1). e On ADC map, the mean ADC value was 1.35 × 10−3 mm2/s. f On sagittal contrast-enhanced fat-saturated T1WI, the manifestation was
similar to that shown in Fig. 2c
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Fig. 3 Female, 18 years, luteinized thecoma on the right ovary. a Axial T1WI showed a relatively large mass with isointensity (arrow). b On axial
fat saturated T2WI, the mass (long arrow) showed heterogeneous isointensity compared with the myometrium. Hyperintensity in the mass represented
degenerative changes. Minor-volume of ascites (short arrow) and ipsilateral ovary (short bold arrow) were present. This mass was accompanied with
endometrial hyperplasia (long bold arrow). c On axial contrast-enhanced fat-saturated T1WI, the mass revealed marked enhancement (long arrow),
similar with the myometrium (short arrow). d On DWI, the mass showed very high signal (grade 3). e On ADC map, the mean ADC value was 1.45 × 10
−3 mm2/s. f On sagittal T2WI, the manifestation was similar to Fig. 3b
Fig. 4 Female, 59 years, a cystic-solid fibrothecoma on the left
side (arrow)
Fig. 5 Female, 63 years, fibrothecoma on the left side (long arrow).
Sagittal T2WI showed the peripheral subcapsular cystic areas
(short arrow)
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AUC and specificity could be achieved by using the low-
est ADC value than the mean ADC value (lowest ADC
vs mean ADC: cutoff value, 1.02 × 10−3 mm2/s vs 0.96 ×
10−3 mm2/s; AUC, 0.861 vs 0.842; 95 % confidence inter-
val of AUC, 0.781–0.942 vs 0.754–0.930; sensitivity, 71.4
vs 85.7 %; specificity, 87.5 vs 67.5 %; accuracy: 80.0 vs
76.0 %) (Fig. 7). The multivariate logistic regression ana-
lysis showed that shape, signal intensity on T2WI, cap-
sule, and the lowest ADC value were the significant
indicators in discriminating thecomas/fibrothecomas
from malignant pelvic solid tumors. The statistical re-
sults of the univariate analysis and multivariate logistic
regression analysis are summarized in Table 2.
Some other features of thecomas/fibrothecomas are
summarized in Table 3. Comparison of degenerative
changes between tumors larger and those smaller than
6 cm is summarized in Table 4.
Discussion
Thecoma/fibrothecoma is a subtype of sex-cord stromal
ovarian tumors with complicated image manifestation
that may occasionally result in a misdiagnosis of ovarian
malignancy. A correct diagnosis is important because
different diagnoses bring about different management
strategies. Conventional MRI combined with DWI is
confirmed very valuable in the diagnosis of thecomas/
fibrothecomas and in the differential diagnosis between
benign and malignant ovarian tumors [12, 13].
Thecomas/fibrothecomas mostly affect menopausal
and postmenopausal women, but they can also occur in
young patients [6]. They usually grow into relatively
large masses, and the adjacent tissues are often com-
pressed [4]. Capsule and border are important aspects in
the differential diagnosis between benign and malignant
lesions. Results in our study showed that capsule is an
independent indicator in differentiating thecomas/
fibrothecomas from malignant pelvic solid tumor.
Though border was not significantly different between
groups in the multivariate logistic regression, malignancy
should still be taken into consideration when an unclear
border appeared. In some cases, ascites was present in
patients with thecomas/fibrothecomas. In our study,
most tumors had accompanying pelvic fluid. Among
these patients, 73.5 % only had minor- or small-volume
of ascites and only 11.8 % had a large volume. Theco-
mas/fibrothecomas with ascites and pleural effusions are
known as Meigs syndrome. In the present study, only
two patients (5.9 %) had pleural effusions and ascites
simultaneously, reflecting the low incidence of this
phenomenon; previous literature has shown similar re-
sults [6, 14–16]. In the malignant pelvic masses group,
large-volume of ascites occurred in more than half of
the patients, a much higher percentage than thecomas/
fibrothecomas. Nevertheless, ascites between groups was
not significantly different in the multivariate logistic re-
gression analysis, which indicated that ascites could not
be regarded as an independent indicator in their differ-
ential diagnosis.
Conventional T1WI and T2WI provide abundant in-
formation regarding the pathological features of tumors.
In the present study, all thecomas/fibrothecomas showed
isointensity on T1WI, which was consistent with a study
Fig. 6 Female, 85 years, serous adenocarcinoma on the left ovary. a Axial T1WI showed a irregular mass with isointensity (arrow). b On axial fat-
saturated T2WI, the mass was hyperintense (arrow) compared with the myometrium (not shown). c On axial contrast-enhanced fat-saturated
T1WI, the mass (arrow) revealed less enhancement than myometrium (not show). d On DWI, the mass appeared as a very high signal (grade 3).
e On the ADC map, the mean ADC value was 0.49 × 10−3 mm2/s. f On sagittal T2WI, the manifestation was similar to Fig. 6b
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performed by Zhang et al. [17]. On T2WI, hypo-, iso-,
hyper-, and mixed intensity occurred in 52.8, 25.0, 5.6,
and 16.7 % of tumors, respectively. In a study conducted
by Chung et al. [12], 55.6 and 44.4 % thecomas/fibrothe-
comas showed low and high signal intensity on T2WI,
respectively, which was comparable with our study. In
our opinion, the hypointensity on T2WI were associated
with the component of abundant fibroblasts and the
relatively hyperintensity had some relationship with the
lipid containing theca-like cells or stromal edema in the
tumors. The variable proportion of theca-like cells
and fibroblasts contributed to the mixture of manifes-
tations on T2WI. In the malignant pelvic solid masses
group, all patients showed isointensity on T1WI and
hyperintensity on T2WI. All these results indicate
that isointensity on T1WI and hypo- to isointensity
on T2WI is the characteristic manifestation of theco-
mas/fibrothecomas and hyperintensity on T2WI was a
significant indicator of pelvic malignant solid tumors
(P = 0.006, OR = 117.274).
Table 1 Comparison of magnetic resonance imaging characteristics of thecomas, fibrothecomas, and malignant pelvic solid masses
Image features Thecoma Fibrothecoma Total Malignant pelvic solid mass
Shape
Round/oval 83.3 %(5/6)a 70.0 %(21/30) 72.2 %(26/36) 17.5 %(7/40)
Lobulated 16.7 %(1/6) 26.7 %(8/30) 25.0 %(9/36) 7.5 %(3/40)
Irregular 0 3.3 %(1/30) 2.8 %(1/36) 75.0 %(30/40)
Signal intensity
T1WI
Iso- 100 %(6/6) 100 %(30/30) 100 % (36/36) 100 %(40/40)
T2WI
Hypo- 16.7 %(1/6) 60.0 %(18/30) 52.8 %(19/36) 0
Iso- 50.0 %(3/6) 20.0 %(6/30) 25.0 %(9/36) 0
Hyper- 33.3 %(2/6) 0 5.6 %(2/36) 100 %(40/40)
Mixed 0 20.0 %(6/30) 16.7 %(6/36) 0
Enhancement degree
Minor 0 70.0 %(21/30) 58.3 %(21/36) 10.0 %(4/40)
Mild 66.7 %(4/6) 30.0 %(9/30) 36.1 %(13/36) 50.0 %(20/40)
Marked 33.3 %(2/6) 0 5.6 %(2/36) 35.0 %(14/40)
Severe 0 0 0 5.0 %(2/40)
DWI signal
Grade 1 0 65.5 % (19/29) 54.3 %(19/35) 2.5 %(1/40)
Grade 2 33.3 %(2/6) 27.6 %(8/29) 28.6 %(10/35) 10.0 %(4/40)
Grade 3 66.7 %(4/6) 6.9 %(2/29) 17.1 %(6/35) 87.5 %(35/40)
Pelvic fluid
None 0 17.9 %(5/28) 14.7 %(5/34) 12.5 %(5/40)
Present 100 %(6/6) 82.1 %(23/28) 85.3 %(29/34) 87.5 %(35/40)
Minor 50.0 %(3/6) 46.4 %(13/28) 47.1 %(16/34) 15.0 %(6/40)
Small 33.3 %(2/6) 25.0 %(7/28) 26.5 %(9/34) 15.0 %(6/40)
Large 16.7 %(1/6) 10.7 %(3/28) 11.8 %(4/34) 57.5 %(23/40)
Border
Clear 100 %(6/6) 100 %(30/30) 100 %(36/36) 27.5 %(11/40)
Not clear 0 0 0 72.5 %(29/40)
Capsule
Present 100 %(6/6) 96.7 %(29/30) 97.2 %(35/36) 52.5 %(21/40)
Absent 0 3.3 %(1/30) 2.8 %(1/36) 47.5 %(19/40)
T1WI T1 weighted imaging, T2WI T2 weighted imaging, DWI diffusion-weighted imaging, hypo hypointensity, iso isointensity, hyper hyperintensity
a Percentage
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Previous studies [3, 4, 7, 14, 17] confirmed that theco-
mas/fibrothecomas in most cases showed minor to mild
enhancement due to poor blood supply. In our study,
58.3 % (21/36) and 36.1 % (13/36) of masses showed
minor and mild enhancement, respectively, which was
comparable to previous studies. Only 5.6 % (2/36) of tu-
mors showed marked enhancement in the present study
and both of them were thecomas, which indicates that
fibrothecomas with more theca-like cell components
seemed to showed higher enhancement and it was more
likely to be a thecoma than fibrothecoma when a lesion
appears with marked enhancement [7]. Conversely, in
malignant pelvic masses, the enhancement degree was
variable owing to the diversity of tumor constitution.
The multivariate logistic regression analysis showed that
enhancement degree was not a significant indicator in
the differential diagnosis between groups, which may be
caused by the tumor constitution diversity of the malig-
nant pelvic solid tumors.
Despite the characteristics observed with conventional
MRI approaches, it is still difficult to differentiate these
two groups of diseases. DWI is a functional imaging
method that reflects water molecule motion and is re-
cently used to improve the diagnostic accuracy of MRI
in pelvic masses [13, 18]. The movement of water mole-
cules in body tissues is impeded by interactions with cell
membranes, intracellular organelles, matrix fibers, and
hydrophobic macromolecules. Moreover, ADC value is a
quantitative expression to reflect water diffusion in tis-
sues. Generally, when high signal on DWI or low ADC
values are detected, a malignancy or the presence of
hypercellularity should be taken into consideration [13,
19–21]. DWI signal intensity and ADC values of benign
and malignant tumors should be different owing to their
different pathological bases, thus aiding in discriminat-
ing thecomas/fibrothecomas from other malignant pelvic
solid tumors.
In the present study, grade 1 to 3 signal on DW-MRI
occurred in 54.3 % (19/35), 28.6 % (10/35), and 17.1 %
(6/35) of thecomas/fibrothecomas, respectively. Grade 1
and grade 3 signals differed significantly between theco-
mas/fibrothecomas and malignant pelvic masses (54.3 vs
2.5 %, 17.1 vs 87.5 %, respectively), which were of great
importance in their differential diagnosis. In our cohort,
DWI signal intensity of thecomas/fibrothecomas varied
from low to very high, which may be associated with the
variable component of fibroblasts and thecalike cells.
Notably, all six thecomas showed grade 2 and 3 signal
intensity on DWI, and grade 1 signal intensity was not
present. In a study performed by Chung et al. [12], low
and high signal on DWI in fibromas accounted for 93.3
and 6.7 % while in thecomas/fibrothecomas, they
accounted for 28.6 and 71.4 %, respectively. Their study
also showed that both thecomas included in their study
showed high intensity on DWI, which is in agreement
with our results. Together, our studies indicate that the-
comas/fibrothecomas with more theca-like cell content
and less fibroblast content tend to have relatively high
signal intensity on DWI and vice versa. Therefore, the-
comas are more likely to have high signals, fibromas
tend to show low signal, and fibrothecomas can show a
mixture of low to high signals on DWI.
As mentioned previously, ADC value is a quantitative
expression of the diffusion characteristics of tissues and
Fig. 7 Comparative diagnostic value of different ADC values for differentiating thecomas/fibrothecomas from malignant pelvic solid tumors
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provides the optimal application of imaging method for
the quantitative evaluation of different lesions in vivo.
ADC value has been proved to be a useful tool in the
differential diagnosis between benign and malignant le-
sions [22–24]. In our study, the lowest and mean ADC
values of thecomas/fibrothecomas were significantly
higher than that of malignant pelvic solid masses (P <
0.001). Higher AUC and specificity could be achieved by
using the lowest ADC value than the mean ADC value,
which indicated the former performed better in this as-
pect. Multivariate logistic regression analysis showed
that the lowest ADC value was a significant indicator in
the differential diagnosis between groups (P = 0.006, OR
= 6467.870). These results implied that ADC value, espe-
cially the lowest ADC value, was very valuable in distin-
guishing thecomas/fibrothecomas from malignant pelvic
solid tumors. However, in a study conducted by Zhang
et al. [17], there was no significant difference in ADC
values between thecomas/fibrothecomas and other solid
ovarian masses, even between benign and malignant
masses. This discrepancy may be associated with differ-
ent b values selected (b = 700 mm−2/s in their study) and








Multivariate logistic regression analysis
B S.E. Wals df P OR Lower limita Upper limita
Age (years) 58.5 ± 12.7 55.3 ± 14.5 0.302 –
Size (mm) 70.3 ± 41.8 78.7 ± 39.5 0.376 –
Shape <0.001 7.977 2 0.019
Round/oval 25 7 Reference
Lobulated 9 3 −0.676 1.582 0.182 1 0.669 0.509 0.023 11.299
Irregular 1 30 7.652 2.710 7.974 1 0.005 2105.780 10.390 426777.060





Enhancement degree <0.001 0.256
Minor 20 4 Reference
Mild 13 20 0.149
Marked 2 14 0.062
Severe 0 2 1.000
Pelvic fluid 0.001 0.436
None 4 5 Reference
Minor 16 6 0.241
Small 9 6 0.981
Large 4 23 0.490
Border <0.001 21.936 2973.934 0.000 1 0.994 3.364E9 0.000
Clear 35 11
Not clear 0 29
Capsule <0.001 6.105 2.972 4.221 1 0.040 448.142 1.324 151649.370
Present 34 21
Absent 1 19
Lowest ADC <0.001 8.775 3.208 7.483 1 0.006 6467.870 12.032 3476890.705
>1.02b 25 5
<1.02b 10 35
One case lacking the data of ADC values was not used in the statistical analysis
B Value partial regression coefficient, S.E. partial regression coefficient standard errors, OR odds ratio
a95 % CI (confidence interval) of OR
b×10−3 mm2/s
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different tumor constitutions of pelvic solid masses se-
lected in our two cohorts (five benign tumors were in-
cluded in their cohort). Besides, manually placing the
ROI in our two studies had the potential risk of meas-
urement error. In the present study, the relatively low
ADC values of thecomas/fibrothecomas likely have
something to do with T2 black out effect, densely ar-
ranged spindle cells and thecal cells, and network of col-
lagen fibers within the extracellular matrix. However,
owing to their benign nature, the ADC value of theco-
mas/fibrothecomas was still apparently higher than ma-
lignant pelvic solid masses. When the lowest ADC value
of 1.02 × 10−3 mm2/s was used as the cutoff value, sensi-
tivity, specificity, and the highest accuracy were 71.4,
87.5, and 80.0 %, respectively. To the best of our know-
ledge, no studies have determined and compared the
validity of different ADC values in differentiating theco-
mas/fibrothecomas from malignant pelvic solid masses
by the ROC curve analysis. All these results confirmed
the great value of ADC measurements in the differential
diagnosis between these two groups of diseases.
Some other characteristics of thecomas/fibrothecomas
include (1) Component: thecomas/fibrothecomas are
mostly solid masses and predominantly cystic or mixed
cystic-solid ones are rare. In the present study, cystic-
solid tumors accounted for only 13.9 % (5/36) of cases.
(2) Degenerative changes: degenerative changes can
occur due to insufficient blood supply as tumors grow. In
the present study, degenerative changes presented in
63.9 % (23/36) of patients, among which tiny degenerative
changes (<5 %) accounted for 30.6 % (11/36). It has been
previously reported that thecomas/fibrothecomas larger
than 6 cm more often show degenerative changes [3, 7,
14]. Our study was in agreement with these reports. In
our research, degenerative changes occurred in 94.4 %
(17/18) lesions larger than 6 cm, while in lesions <6 cm,
the incidence rate was 33.3 % (6/18). (3) Peripheral sub-
capsular cystic areas: in a study conducted by Shinagare et
al. [7], peripheral subcapsular cystic areas, which repre-
sented edematous change on pathologic examination, oc-
curred in 49 % of tumors. In the present study, 58.3 % of
thecomas/fibrothecomas showed this feature. (4) Ipsilat-
eral ovary: in our study, the ipsilateral ovary was seen in
33.3 % (12/36) patients, which was similar to a study by
Oh et al. (46 %) [25]. (5) Endometrial hyperplasia and
endometrial carcinoma: thecomas/fibrothecomas are fre-
quently estrogenic and are occasionally accompanied with
associated manifestations such as endometrial hyperplasia
and endometrial carcinoma [4, 7]. In a report by Li et al.
[4], endometrial hyperplasia and endometrial carcinoma
occurred in 10.5 and 5.2 % of patients with thecomas/
fibrothecomas. In our study, 8.8 % (3/34) of patients had
endometrial hyperplasia and no patient had endometrial
carcinoma. (6) Luteinized thecomas: luteinized thecomas
are uncommon and include any thecomas that containing
luteinized cells. They more often occur in younger pa-
tients than typical thecomas, and 30 % of patients with lu-
teinized thecomas present under the age of 30 years [26,
27]. In our study, luteinized thecoma occurred in one fe-
male 18 years of age.
There were several limitations to our study. First, be-
cause of the retrospective nature of our study, biases
may inevitably occur and some prospective studies
should be performed in future. Second, the semiquanti-
tative evaluation of some characteristics like ascites and
degenerative changes of the tumors in the present study
was not accurate enough owing to the lack of reliable
measurement methods. Third, time-signal intensity
curve were not obtained after administration of contrast
medium in our study and perfusion weighted image
(PWI) should be added in the subsequent studies. In
addition, though the sample size in our study is the lar-
gest among the literature focusing on MRI characteris-
tics of thecomas/fibrothecomas, further work with a
larger sample size is still needed to provide reliable refer-
ence for gynecologists. Nevertheless, our study also has
some positive results. First, to the best of our knowledge,
our study is one of the very few reporting DWI charac-
teristics of thecomas/fibrothecomas, and both of the
previous studies had very small sample sizes (n = 18 and
Table 3 Some other features of thecomas/fibrothecomas
Image features Thecoma Fibrothcoma Total
Component
Solid 100 %(6/6)a 83.3 %(25/30) 86.1 %(31/36)
Cystic-solid 0 16.7 %(5/30) 13.9 %(5/36)
Degenerative changes
None 50.0 %(3/6) 33.3 %(10/30) 36.1 %(13/36)
Present 50.0 %(3/6) 66.7 %(20/30) 63.9 %(23/36)
<5 % 0 36.7 %(11/30) 30.6 %(11/36)
5–30 % 33.3 %(2/6) 26.7 %(8/30) 27.8 %(10/36)
>30 % 16.7 %(1/6) 3.3 %(1/30) 5.6 %(2/36)
Peripheral cystic areas 83.3 %(5/6) 53.3 %(16/30) 58.3 %(21/36)
Ipsilateral ovary 33.3 %(2/6) 33.3 %(10/30) 33.3 %(12/36)
Endometrial hyperplasia 33.3 %(2/6) 3.6 %(1/28) 8.8 %(3/34)
aPercentage
Table 4 Comparison of degenerative changes between tumors
larger and those smaller than 6 cm
<6 cm >6 cm
None 66.7 %(12/18) 5.6 %(1/18)
Present 33.3 %(6/18) 94.4 %(17/18)
<5 % 22.2 %(4/18) 38.9 %(7/18)
5–30 % 11.1 %(2/18) 44.4 %(8/18)
>30 % 0 11.1 %(2/18)
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9, respectively) [12, 17]. Second, our study is the first to
differentiate thecomas/fibrothecomas from malignant
pelvic solid masses using different ADC values by the
ROC curve analysis.
Conclusions
In summary, thecomas/fibrothecomas are rare benign
ovarian tumors and occasionally are misdiagnosed as pel-
vic malignancies. Most thecomas/fibrothecomas show iso-
intensity on T1WI and hypo/isointensity on T2WI with
minor to mild enhancement. They are usually round or
oval with a clear margin, and degenerative changes occur
more often in larger lesions. Ascites and elevated CA125
levels can occur in some cases as well. Conversely, most
malignant pelvic masses are hyperintensity on T2WI with
irregular morphology and unclear border. Signal intensity
on DWI is useful in their differential diagnosis. Shape, sig-
nal intensity on T2WI, capsule, and the lowest ADC value
were significant indicators in the differential diagnosis be-
tween groups. The combination of DWI and conventional
MRI is of great value in the diagnosis of thecomas/
fibrothecomas and their differential diagnosis with malig-
nant pelvic solid tumors.
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